These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32709434)

  • 1. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Moro PL; Woo EJ; Marquez P; Cano M
    Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.
    Moro PL; Arana J; Cano M; Menschik D; Yue X; Lewis P; Haber P; Martin D; Broder K
    Clin Infect Dis; 2012 Jun; 54(11):1608-14. PubMed ID: 22441652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
    Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
    Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
    Haber P; Moro PL; Cano M; Lewis P; Stewart B; Shimabukuro TT
    Vaccine; 2015 Apr; 33(16):1987-92. PubMed ID: 25678241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
    Haber P; Moro PL; Cano M; Vellozzi C; Lewis P; Woo EJ; Broder K
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):205-13. PubMed ID: 26407428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
    Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
    Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
    Schmader KE; Liu CK; Harrington T; Rountree W; Auerbach H; Walter EB; Barnett ED; Schlaudecker EP; Todd CA; Poniewierski M; Staat MA; Wodi P; Broder KR
    JAMA Netw Open; 2021 Jan; 4(1):e2031266. PubMed ID: 33443580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL
    Vaccine; 2022 Feb; 40(7):1026-1030. PubMed ID: 35031148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Moro PL; Marquez P
    Vaccine; 2021 Jan; 39(4):678-681. PubMed ID: 33358703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P; Arana J; Pilishvili T; Lewis P; Moro PL; Cano M
    Vaccine; 2016 Dec; 34(50):6330-6334. PubMed ID: 27836437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.